Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome

Interventions

DRUG: NS-229
DRUG: Placebo

Sponsor

NS Pharma, Inc.

Collaborators

[object Object]